Mycophenolat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil acts on the immune system to reduce lymphocyte proliferation, making it useful in several transplant and autoimmune settings.

• Kidney transplant rejection: helps prevent acute and chronic rejection episodes.
• Heart transplant rejection: reduces the risk of graft failure.
• Liver transplant rejection: supports long‑term graft survival.
• Lupus nephritis: diminishes renal inflammation and proteinuria.

• Mycophenolate Mofetil is converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase. This blocks de novo guanosine nucleotide synthesis in activated T and B lymphocytes, leading to reduced proliferation and diminished immune responses without affecting resting cells.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools.
• Vomiting: occasional emesis.
• Abdominal pain: cramping or discomfort.
• Headache: transient cephalgia.
• Upper respiratory infection: mild viral symptoms.

Serious or Rare Side Effects

• Leukopenia: significant reduction in white blood cells.
• Anemia: decreased red blood cell count.
• Severe infections: opportunistic or bacterial infections.
• Malignancy: increased risk of certain cancers.
• Hepatic dysfunction: elevated liver enzymes.
• Progressive multifocal leukoencephalopathy: rare viral brain infection.

Before initiating therapy, clinicians should assess baseline labs and patient risk factors.

• Monitor blood counts: regular CBC to detect leukopenia or anemia.
• Monitor renal function: assess serum creatinine and eGFR.
• Monitor liver enzymes: check ALT/AST periodically.
• Avoid live vaccines: risk of uncontrolled infection.
• Counsel on infection risk: advise prompt reporting of fever or signs of infection.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil can interact with several drugs, altering its efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of mycophenolic acid.
• Azathioprine: additive bone‑marrow suppression.
• Cyclosporine: increases mycophenolate exposure, raising toxicity risk.
• Rifampin: induces metabolism, decreasing drug levels.
• Live vaccines: may cause severe infection.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may exacerbate renal impairment.
• NSAIDs: increase risk of renal dysfunction when combined.
• Warfarin: may alter INR, requiring closer monitoring.